Gentler conditioning regimen before donor stem cell transplant for high-risk MDS or AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a less intense chemotherapy and radiation combination (called TMLI, fludarabine, and melphalan) before a stem cell transplant from a matched donor. The goal is to help prepare your body for the transplant while reducing side effects, so it may be a good option if you have high-risk MDS or AML and cannot tolerate the standard, more intensive conditioning regimen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 or older, or you have other health problems that make a standard intensive transplant conditioning regimen too risky.
- You have high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) – either with active disease (at least 5% blasts in the bone marrow) or with measurable residual disease (MRD) while in remission.
- You have a sibling or unrelated donor who is a close match (8/8, with a few minor mismatches allowed).
- Your liver, kidney, lung, and heart function must be within the limits required for this trial (e.g., kidney function with creatinine clearance of 80 mL/min or more, lung function at least 50% of expected, and heart ejection fraction of 50% or more).
- You must not have had a previous allogeneic (donor) transplant at any time, or an autologous (your own) transplant within the last year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special combination of chemotherapy drugs (called a conditioning regimen) given before a half-matched stem cell transplant for older adults with acute myeloid leukemia (AML) in their first remission. The goal is to make the transplant safer and more effective for people aged 55 to 75.
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
This trial is testing a more targeted way to deliver radiation before a stem cell transplant, aiming to reduce side effects while helping the new cells engraft. It includes two different radiation doses, one for first-time transplant patients and another for those who have relapsed after a prior transplant.
This trial tests a gentler chemotherapy regimen (fludarabine and treosulfan) before a stem cell transplant from a half-matched donor. It aims to make the transplant safer and more effective for older or frailer patients with acute myeloid leukemia.
This trial tests a precise type of radiation called intensity modulated total marrow irradiation before a stem cell transplant. It aims to destroy cancer cells while reducing side effects for patients with high-risk leukemia or myelodysplastic syndrome.
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.